Bioauxilium specializes in the design, development and manufacturing of ready-to-use TR-FRET assay kits that simplify laboratory workflow and accelerate drug discovery and life sciences research.
At the SLAS2023 International Conference and Exhibition in San Diego, we announced the expansion of our no-wash THUNDER™ time-resolved Förster resonance energy transfer (TR-FRET) technology portfolio by introducing six new Biomarker research Assay Kits, a Reader Control Kit, and an enhanced Assay Development Service for drug discovery research.
The new offerings include a panel of six key mouse inflammatory cytokines (CCL-2/MCP1, IFN-beta, IFN-gamma, IL-2, IL-6, and TNF-alpha), expanding the company’s portfolio to a total of 100 cell-based assay kits (76 Cell Signaling Kinases, 23 Biomarkers, and a cAMP Assay). The innovative, ready-to-use Reader Control Kit allows users to assess in just 10 minutes the suitability of TR‑FRET compatible microplate readers to perform Europium-based TR-FRET measurements.
The new Assay Development Service offers three types of custom assay solutions: labeling of antibodies with BioAuxilium’s proprietary TR-FRET fluorophores, custom assay development services, and custom kit development services. These comprehensive, yet flexible custom solutions are designed to fast-track assay development, while further reducing risk, turnaround time, and cost.
See the Business Wire’s press release here.
